| Patent Number |
Title Of Patent |
Date Issued |
| 7316915 |
Bak binding protein, DNA encoding the protein, and methods of use thereof |
January 8, 2008 |
| The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. |
| 7118743 |
Bispecific molecules cross-linking ITIM and ITAM for therapy |
October 10, 2006 |
| The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor |
| 7112327 |
Inhibition of complement activation |
September 26, 2006 |
| The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragmen |
| 7108989 |
Apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof |
September 19, 2006 |
| The present invention provides a method of screening for a biological modifier that modulates apoptosis-induced cell death by contacting a cell expressing CDN-1 or fragments or variants thereof with a potential biological modifier and measuring the level of apoptosis-induced cell dea |
| 7045604 |
Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use |
May 16, 2006 |
| An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of .alpha.SARP polypeptide; a host cell transformed with an isolated polynucleotide or |
| 7045596 |
Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use |
May 16, 2006 |
| An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of .alpha.SARP polypeptide; a host cell transformed with an isolated polynucleotide or |
| 6998468 |
Anti-C2/C2a inhibitors of complement activation |
February 14, 2006 |
| The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, |
| 6956107 |
Inhibitors of complement activation |
October 18, 2005 |
| The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragmen |
| 6903195 |
Methods and compositions for detecting CDN apoptosis-modulating proteins |
June 7, 2005 |
| The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided. |
| 6787524 |
CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
September 7, 2004 |
| The invention relates to a method of stimulating antibody-dependent cellular cytotoxicity to enhance the elimination of IgE-bearing B-cells comprising administering to a mammal an anti-IgE antibody, which binds to membrane bound IgE, but does not induce histamine release and administ |
| 6767540 |
Use of antagonists of plasminogen activator inhibitor-1 (PAI-1) for the treatment of asthma and |
July 27, 2004 |
| The invention relates to methods for treatment of asthma and chronic obstructive pulmonary disease (COPD) by administration of antagonists to plasminogen activator inhibitor type-1 (PAI-1). Suitable atagonists include antibodies, peptides, proteins, nucleic acids, small organic molec |
| 6685930 |
Methods and substances for recruiting therapeutic agents to solid tumors |
February 3, 2004 |
| Disclosed is a method of using bifunctional binding molecules, such as two linked V.sub.H -V.sub.L single chain binding molecules, to recruit a therapeutic agent to a solid tissue site. The therapeutic agent is administered separately from the binding molecules and following the admi |
| 6657050 |
Chimeric viral-neutralizing immunoglobulins |
December 2, 2003 |
| Chimeral viral-neutralizing, particularly HIV-neutralizing, immunoglobulins made up of a non-human antigen binding region and a human constant region are described. |
| 6586395 |
Apoptosis-modulating proteins |
July 1, 2003 |
| The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to novel homologs of bcl-2 de |
| 6534058 |
Anti-C5 monoclonal antibodies |
March 18, 2003 |
| The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include |
| 6441135 |
Bak binding protein, DNA encoding the protein, and methods of use thereof |
August 27, 2002 |
| The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. |
| 6436639 |
Bak promoter expression system |
August 20, 2002 |
| Polynucleotides which regulate the expression of a gene involved in apoptosis is described. Also provided are methods for identifying agents that modulate expression of a gene involved in apoptosis. |
| 6433155 |
Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use |
August 13, 2002 |
| An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of .alpha.SARP polypeptide; a host cell transformed with an isolated polynucleotide or |
| 6309880 |
Antibodies specific for CD4-binding domain of HIV-1 |
October 30, 2001 |
| A particular epitope located within the CD4-binding region of gpl20 of HIV-1, and antibodies specific for the epitope which can inhibit HIV-1 infection of human cells by diverse strains and isolates of the virus, is disclosed. The antibodies are useful for a number of purposes, including |
| 6197298 |
Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators |
March 6, 2001 |
| Several forms of immunoregulatory substances are derived from monoclonal antibodies (MAbs) that are specific for a T cell surface antigen, such as CD3, TCR, CD4, or CD8 on T cells. The substances include: a mixture of F(ab').sub.2 fragments (or other divalent binding molecules which lack |
| 6177548 |
Enhanced aggregate removal from bulk biologicals using ion exchange chromatography |
January 23, 2001 |
| Disclosed are methods and processes for removing aggregates and other impurities from partially purified protein bulk product, in particular, from partially purified monoclonal antibody, using anion exchange chromatography. In such methods and processes, the pH of the sample is adjus |
| 6129916 |
Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
October 10, 2000 |
| Disclosed are conjugates including a polymer backbone or microbead and binding molecules, such as Fv, Fab, or F(ab').sub.2 fragments of monoclonal antibodies or whole antibodies that are bound through their Fc carbohydrate moieties or have their Fc portion modified so that they canno |
| 6117982 |
Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immu |
September 12, 2000 |
| Several forms of immunoregulatory substances are derived from monoclonal antibodies (MAbs) that are specific for a T cell surface antigen, such as CD3, TCR, CD4, or CD8 on T cells. The substances include: a mixture of F(ab').sub.2 fragments (or other divalent binding molecules which lack |
| 6106835 |
Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modul |
August 22, 2000 |
| Several forms of immunoregulatory substances are derived from monoclonal antibodies (MAbs) that are specific for a T or B cell surface antigen, such as CD3, TCR, CD4, or CD8 on T cells or membrane-bound immunoglobulins on B cells. The substances include: a mixture of F(ab').sub.2 fragmen |
| 5981278 |
Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therap |
November 9, 1999 |
| Monoclonal antibodies are revealed which bind to the gp 120 protein on the envelope of HIV-1. These antibodies neutralize HIV-1. They inhibit the rate of infection of T cells, and also inhibit syncytium formation. Further, the antibodies are group-specific and neutralize different st |
| 5908626 |
Hybrid with interferon-.beta. and an immunoglobulin Fc joined by a peptide linker |
June 1, 1999 |
| Disclosed is a hybrid recombinant protein consisting of human interferon-.beta., and a human immunoglobulin Fc fragment, preferably .gamma.4 chain, joined by a peptide linker comprising the sequence Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser (SEQ ID NO:1). |
| 5854400 |
Monoclonal antibodies which neutralize HIV-1 infection |
December 29, 1998 |
| Murine monoclonal antibodies and related products such as antibody fragments, immunotoxins, human and humanized antibodies are disclosed, all of which bind to the gp120 protein on the envelope of HIV-1. These antibodies and related products neutralize HIV-1. They inhibit the infectio |
